289 related articles for article (PubMed ID: 28490888)
21. Efficacy and Tolerability of First Line Arsenic Trioxide in Combination With All-Trans Retinoic Acid in Patients With Acute Promyelocytic Leukemia: Real Life Experience.
Autore F; Chiusolo P; Sorà F; Giammarco S; Laurenti L; Innocenti I; Metafuni E; Piccirillo N; Pagano L; Sica S
Front Oncol; 2021; 11():614721. PubMed ID: 34336637
[TBL] [Abstract][Full Text] [Related]
22. Consolidation therapy of arsenic trioxide alternated with chemotherapy achieves remarkable efficacy in newly diagnosed acute promyelocytic leukemia.
Liu CC; Wang H; Wang WD; Zhu MY; Geng QR; Lu Y
Onco Targets Ther; 2015; 8():3297-303. PubMed ID: 26622182
[TBL] [Abstract][Full Text] [Related]
23. Delayed recovery of normal hematopoiesis in arsenic trioxide treatment of acute promyelocytic leukemia: a comparison to all-trans retinoic acid treatment.
Shinjo K; Takeshita A; Sahara N; Kobayashi M; Nakamura S; Shigeno K; Naito K; Maekawa M; Ohnishi K; Ohno R
Intern Med; 2005 Aug; 44(8):818-24. PubMed ID: 16157979
[TBL] [Abstract][Full Text] [Related]
24. Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial.
Platzbecker U; Avvisati G; Cicconi L; Thiede C; Paoloni F; Vignetti M; Ferrara F; Divona M; Albano F; Efficace F; Fazi P; Sborgia M; Di Bona E; Breccia M; Borlenghi E; Cairoli R; Rambaldi A; Melillo L; La Nasa G; Fiedler W; Brossart P; Hertenstein B; Salih HR; Wattad M; Lübbert M; Brandts CH; Hänel M; Röllig C; Schmitz N; Link H; Frairia C; Pogliani EM; Fozza C; D'Arco AM; Di Renzo N; Cortelezzi A; Fabbiano F; Döhner K; Ganser A; Döhner H; Amadori S; Mandelli F; Ehninger G; Schlenk RF; Lo-Coco F
J Clin Oncol; 2017 Feb; 35(6):605-612. PubMed ID: 27400939
[TBL] [Abstract][Full Text] [Related]
25. Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia.
Lou Y; Qian W; Meng H; Mai W; Tong H; Tong Y; Huang J; Jin J
Hematol Oncol; 2014 Mar; 32(1):40-6. PubMed ID: 23963734
[TBL] [Abstract][Full Text] [Related]
26. Combined arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia recurring from previous relapses successfully treated using arsenic trioxide.
Au WY; Chim CS; Lie AK; Liang R; Kwong YL
Br J Haematol; 2002 Apr; 117(1):130-2. PubMed ID: 11918543
[TBL] [Abstract][Full Text] [Related]
27. Acute promyelocytic leukemia.
Douer D
Curr Treat Options Oncol; 2000 Apr; 1(1):31-40. PubMed ID: 12057059
[TBL] [Abstract][Full Text] [Related]
28. [Clinical observation of the short-term efficacy of the treatment with combination of all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) in newly diagnosed acute promyelocytic leukemia (APL)].
Liu YF; Shen ZX; Chen X; Wang AH; Cao Q; Zhu YM; Chen SJ; Chen Z; Wang ZY
Zhonghua Xue Ye Xue Za Zhi; 2003 Jan; 24(1):25-7. PubMed ID: 12679006
[TBL] [Abstract][Full Text] [Related]
29. High efficacy of arsenic trioxide plus all-trans retinoic acid based induction and maintenance therapy in newly diagnosed acute promyelocytic leukemia.
Lou Y; Qian W; Meng H; Mai W; Tong H; Tong Y; Huang J; Jin J
Leuk Res; 2013 Jan; 37(1):37-42. PubMed ID: 23017225
[TBL] [Abstract][Full Text] [Related]
30. Oral arsenic and retinoic acid for high-risk acute promyelocytic leukemia.
Ma YF; Lu Y; Wu Q; Lou YJ; Yang M; Xu JY; Sun CH; Mao LP; Xu GX; Li L; Huang J; Wang HY; Lou LJ; Meng HT; Qian JJ; Yu WJ; Wei JY; Li ZY; Zhu XL; Yan XY; Chen SN; Jin J; Zhu HH
J Hematol Oncol; 2022 Oct; 15(1):148. PubMed ID: 36258250
[TBL] [Abstract][Full Text] [Related]
31. All-Trans Retinoic Acid plus Arsenic Trioxide versus All-Trans Retinoic Acid plus Chemotherapy for Newly Diagnosed Acute Promyelocytic Leukemia: A Meta-Analysis.
Ma Y; Liu L; Jin J; Lou Y
PLoS One; 2016; 11(7):e0158760. PubMed ID: 27391027
[TBL] [Abstract][Full Text] [Related]
32. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: an useful salvage therapy.
Huan SY; Yang CH; Chen YC
Leuk Lymphoma; 2000 Jul; 38(3-4):283-93. PubMed ID: 10830735
[TBL] [Abstract][Full Text] [Related]
33. [Stratification therapy in patients with acute promyelocytic leukemia after a complete remission by all-trans retinoic acid].
Xu JL; Jiang M; Halida Y; Duan XL; Guo XH; Hao JP; Fu ML; Qu JH; Wang L
Zhonghua Yi Xue Za Zhi; 2011 Aug; 91(32):2254-7. PubMed ID: 22094090
[TBL] [Abstract][Full Text] [Related]
34. All-trans retinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia.
Fenaux P; Chomienne C; Degos L
Semin Hematol; 2001 Jan; 38(1):13-25. PubMed ID: 11172536
[TBL] [Abstract][Full Text] [Related]
35. Upfront maintenance therapy with arsenic trioxide in acute promyelocytic leukemia provides no benefit for non-t(15;17) subtype.
Chiang YH; Chang YF; Hsieh RK; Lin J; Chen CG; Lim KH; Lin HC; Chang MC
Asia Pac J Clin Oncol; 2012 Dec; 8(4):330-6. PubMed ID: 22897350
[TBL] [Abstract][Full Text] [Related]
36. [Efficacy analysis of sequential treatment with chemotherapy, ATRA and As(2)O(3) for acute promyelocytic leukemia].
Ma XJ; Ren HY; Cen XN; Qiu ZX; Wang WS; Ou JP; Wang Y; Xu WL; Li Y; Wang MJ; Wang LH; Dong YJ; Yin Y; Liang ZY
Zhonghua Xue Ye Xue Za Zhi; 2010 May; 31(5):328-32. PubMed ID: 21122313
[TBL] [Abstract][Full Text] [Related]
37. [The significance of combined therapy of arsenic trioxide and all-trans retinoic acid in treating acute promyelocytic leukemia].
Tao S; Zhou K; Tang DZ
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2009 Feb; 29(2):111-4. PubMed ID: 19382468
[TBL] [Abstract][Full Text] [Related]
38. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
[TBL] [Abstract][Full Text] [Related]
39. Treatment of acute promyelocytic leukemia with arsenic compounds: in vitro and in vivo studies.
Chen Z; Chen GQ; Shen ZX; Chen SJ; Wang ZY
Semin Hematol; 2001 Jan; 38(1):26-36. PubMed ID: 11172537
[TBL] [Abstract][Full Text] [Related]
40. The role of maintenance therapy in acute promyelocytic leukemia in the first complete remission.
Muchtar E; Vidal L; Ram R; Gafter-Gvili A; Shpilberg O; Raanani P
Cochrane Database Syst Rev; 2013 Mar; (3):CD009594. PubMed ID: 23543579
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
